Payment overview · 2025
General Payments
$1,032.36
30 reported records · 9 companies
Healthcare provider profile · identity verified
Mohamed Sheku Dauda, MD
Allopathic & Osteopathic Physicians|Family Medicine · BALTIMORE, MD · NPI 1124210026
Verified facts
What the public records show
CMS Open Payments records show Mohamed Sheku Dauda, MD received $1,032.36 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $484.93 | 47.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $371.89 | 36.0% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.92 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.20 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.15 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.62 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.30 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.86 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.49 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,032.36 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $371.89 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $341.84 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 77 |
| Gabapentin | Gabapentin | 178 | 46 |
| Losartan Potassium | Losartan Potassium | 153 | 43 |
| Metformin Hcl | Metformin Hcl | 146 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 41 |
| Tramadol Hcl | Tramadol Hcl | 133 | 46 |
| Ibuprofen | Ibuprofen | 131 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 33 |
| Furosemide | Furosemide | 113 | 32 |
| Nifedipine Er | Nifedipine | 113 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 29 |
| Lisinopril | Lisinopril | 101 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 24 |
| Simvastatin | Simvastatin | 79 | 16 |
| Trazodone Hcl | Trazodone Hcl | 77 | 20 |
| Omeprazole | Omeprazole | 76 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 18 |
| Allopurinol | Allopurinol | 67 | 21 |
| Ozempic | Semaglutide | 57 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | 19 |
| Glipizide | Glipizide | 51 | 16 |
| Eliquis | Apixaban | 50 | 15 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Ezetimibe | Ezetimibe | 48 | 12 |
| Meloxicam | Meloxicam | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 16 |
| Levetiracetam | Levetiracetam | 43 | 12 |
| Carvedilol | Carvedilol | 42 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 41 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,032.36 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, INGREZZA, Kerendia, MOUNJARO, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error